Acrivon advances ACR-2316 into randomized dose expansion in Phase 1/2 trial

Reuters2026/08/05 12:31

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Acrivon Therapeutics advanced ACR-2316 into randomized dose expansion in its ongoing Phase 1/2 trial, based on dose-escalation safety and activity observations.
Results have already been presented as interim findings from dose escalation; additional updates are expected as the expansion progresses.
Early outcomes showed durable single-agent anti-tumor activity, including responses in heavily pretreated patients, with tolerability supporting continued development.
The study will randomize 120 mg versus 160 mg once-daily dosing on a weekly 3-days-on, 4-days-off schedule to support final dose selection.
Expansion will focus on biomarker-selected solid tumors, led by lung cancer cohorts, aiming to sharpen the benefit-risk profile for later-stage trials.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acrivon Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608050830PRIMZONEFULLFEED9803960) on August 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Acrivon advances ACR-2316 into randomized dose expansion in Phase 1/2 trial

You may also like

Crypto prices